FindTrial
Sign In

PI3K-beta Inhibitor GSK2636771

DRUG3 trials

Sponsors

National Cancer Institute (NCI)

Conditions

Advanced LymphomaAdvanced Malignant Solid NeoplasmBladder CarcinomaBreast CarcinomaCervical CarcinomaColon CarcinomaColorectal CarcinomaEndometrial Carcinoma

Phase 2

Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
Active, not recruitingNCT02465060
National Cancer Institute (NCI)Advanced Lymphoma, Advanced Malignant Solid Neoplasm, Bladder Carcinoma +49
Start: 2015-08-17End: 2026-12-31Target: 6452Updated: 2026-04-03
Testing GSK2636771 as a Potential Targeted Treatment in Cancers With PTEN Genetic Changes (MATCH-Subprotocol N)
Active, not recruitingNCT04439149
National Cancer Institute (NCI)Advanced Lymphoma, Advanced Malignant Solid Neoplasm, Hematopoietic and Lymphoid Cell Neoplasm +3
Start: 2016-05-05End: 2026-12-31Updated: 2025-11-21
Testing GSK2636771 as a Potential Targeted Treatment in Cancers With PTEN Loss of Expression (MATCH-Subprotocol P)
Active, not recruitingNCT04439188
National Cancer Institute (NCI)Advanced Lymphoma, Advanced Malignant Solid Neoplasm, Hematopoietic and Lymphoid Cell Neoplasm +3
Start: 2016-03-21End: 2026-12-31Updated: 2025-11-19

Related Papers

Phase II Study of Vismodegib in Patients With <i>SMO-</i> or <i>PTCH1</i>-Mutated Tumors: Results From the National Cancer Institute Molecular Analysis for Therapy Choice Eastern Cooperative Oncology Group-American College of Radiology Imaging Network Trial (EAY131) Subprotocol T.
2025-10-09
Comprehensive genomic profiling of matched ctDNA and tissue from patients with less common cancers enrolled in but not eligible for a treatment arm of the NCI-MATCH trial.
Journal of Clinical Oncology2025-05-281 citations
Molecular profiling of plasma from matched NCI-MATCH gynecological cancers.
Journal of Clinical Oncology2024-06-011 citations
Olaparib for childhood tumors harboring defects in DNA damage repair genes: arm H of the NCI-COG Pediatric MATCH trial
The Oncologist2024-05-306 citations
Abstract B007: Concordance between tumor tissue and plasma genotyping in NCI-MATCH Trial (EAY131)
Molecular Cancer Therapeutics2023-12-01
Revolutionizing cancer drug development: Harnessing the potential of basket trials.
2023-11-0720 citations
The NCI-MATCH trial: lessons for precision oncology.
2023-06-15103 citations
Phase II study of crizotinib in patients with <i>MET</i> amplification and <i>MET</i> exon 14 deletion: Results from NCI-MATCH ECOG-ACRIN trial (EAY131) subprotocols C1 and C2.
Journal of Clinical Oncology2023-06-012 citations
Discovery of gene fusions in driver-negative NCI-MATCH screening samples.
Journal of Clinical Oncology2023-06-011 citations
Dabrafenib plus trametinib in BRAFV600E-mutated rare cancers: the phase 2 ROAR trial
Nature Medicine2023-04-14244 citations
National Cancer Institute Combination Therapy Platform Trial with Molecular Analysis for Therapy Choice (ComboMATCH)
Clinical Cancer Research2023-01-2055 citations
Challenges and opportunities associated with the MD Anderson IMPACT2 randomized study in precision oncology
npj Precision Oncology2022-10-2715 citations
Abstract 2438: Determining the role of non-mutated C-Raf kinase in metastatic disease
Cancer Research2022-06-15
Rationale and design of ON-TRK: a novel prospective non-interventional study in patients with TRK fusion cancer treated with larotrectinib.
2022-06-077 citations
Phase II study of vismodegib in patients with <i>SM</i>O or <i>PTCH1</i> mutated tumors: Results from NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol T.
Journal of Clinical Oncology2022-06-013 citations
Molecular predictors of response among patients with MMRd tumors treated on NCI-MATCH Arm Z1D.
Journal of Clinical Oncology2022-06-01
Larotrectinib Treatment for Patients With TRK Fusion-Positive Salivary Gland Cancers
The Oncologist2022-04-1445 citations
Abstract P2-13-24: Distinct HER2 allele specific therapeutic response and preclinical efficacy of poziotinib in metastatic ER+ HER2 mutant breast cancer
Cancer Research2022-02-151 citations
Precision medicine: preliminary results from the Initiative for Molecular Profiling and Advanced Cancer Therapy 2 (IMPACT2) study.
2021-03-1921 citations
Molecular and Immunological Characterization of Biliary Tract Cancers: A Paradigm Shift Towards a Personalized Medicine.
2020-08-0632 citations

17 more papers not shown